Introducing patient-centric SARS-CoV-2 serology testing with Trajan Scientific and Medical and Synexa Life Sciences

Introducing patient-centric SARS-CoV-2 serology testing with Trajan Scientific and Medical and Synexa Life Sciences

February 17, 2021

In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies. Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.

With hemaPEN’s® innovative, easy-to-use design and microsampling technology, large scale screening and sero-surveillance studies post-vaccine roll out can be conducted safely and efficiently, while maintaining social distancing protocols and maintaining patient-centricity, comfort and convenience.

Combining this technology with Synexa’s innovative, market-leading SARS-CoV-2 serology assay - a versatile technology capable of detecting IgG, IgM, IgA and nAb antibody response, as well as their semi-quantification without the need for titration - has yielded a highly competitive and flexible assay, suitable across a wide range of applications.

Through this collaboration, Trajan and Synexa have developed a powerful platform to enable vaccine programs with more convenience and comfort for the patient, while retaining high quality data for understanding the safety and efficacy of vaccines.

If you would like more information about our product and service offering to assist and support your vaccine program, please contact us.

Download
Brochure - SARS-CoV-2 serology testing

Related news
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC's Analyst

More information
www.hemapen.com

Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
media@trajanscimed.com




Also in News

Trajan completes ISO 9001 recertification
Trajan completes ISO 9001 recertification

July 14, 2021

Trajan Scientific and Medical has successfully completed a 3-year ISO 9001:2015 recertification at our Ringwood global headquarters this week, cementing the importance that we place over quality management and continuous improvement for ourselves and all stakeholders.

Read More

Global analytical science and device company Trajan Group announces IPO and $50M capital injection to fuel next phase of growth
Global analytical science and device company Trajan Group announces IPO and $50M capital injection to fuel next phase of growth

May 17, 2021

Global analytical science and device company Trajan Group Holdings Limited (Trajan or the Company) has launched a $90 million IPO to support the next phase of accelerated growth.

Read More

Trajan acquires personalised blood testing business to strengthen move into data-based preventative healthcare
Trajan acquires personalised blood testing business to strengthen move into data-based preventative healthcare

April 16, 2021

Trajan Scientific and Medical (Trajan) has completed the acquisition of the MyHealthTest blood testing service for an undisclosed sum. The acquisition further boosts Trajan’s ability to deliver analytical measurement services to society at a time when preventative healthcare strategies are becoming increasingly important.

Read More